» Articles » PMID: 6297384

Therapeutic Activities of Cefazolin, Cefotaxime, and Ceftazidime Against Experimentally Induced Klebsiella Pneumoniae Pneumonia in Rats

Overview
Specialty Pharmacology
Date 1982 Dec 1
PMID 6297384
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacies of several dosage schedules of cefazolin, cefotaxime, and ceftazidime, started 12 or 36 h after infection, were examined in experimental pneumonia caused by Klebsiella pneumoniae in rats. The therapeutic activities of the cephalosporins were compared with the antibacterial activities in vitro and the serum concentration curves. The course of experimental pneumonia was rapid and characterized by tissue necrosis. Response to antimicrobial treatment was evaluated with respect to mortality and numbers of bacteria in lung (left lobe), blood, and pleural fluid. When antibiotic treatment was started early, i.e., 12 h after bacterial inoculation, cefotaxime and ceftazidime were equally effective and superior to cefazolin. Eleven doses of 10 mg of cefotaxime or ceftazidime per kg or 11 doses of 60 mg of cefazolin per kg were required to improve the survival rate. With a delay in administration to 36 h after inoculation, the efficacy of the cephalosporins decreased markedly. In the three dosages tested, cefazolin was ineffective. Survival improved with the administration of nine doses of 60 mg of cefotaxime per kg or nine doses of 10 mg of ceftazidime per kg. These results are not in accordance with the ratio of in vitro activities of cefotaxime and ceftazidime or the serum concentration curves.

Citing Articles

The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.

Goessens W, Mouton J, Ten Kate M, Sorgel F, Kinzig M, Bakker-Woudenberg I Antimicrob Agents Chemother. 2012; 57(1):643-6.

PMID: 23129049 PMC: 3535950. DOI: 10.1128/AAC.01154-12.


Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Bakker-Woudenberg I, Ten Kate M, Goessens W, Mouton J Antimicrob Agents Chemother. 2006; 50(9):2919-25.

PMID: 16940082 PMC: 1563558. DOI: 10.1128/AAC.00859-05.


Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.

Ruijgrok E, Fens M, Bakker-Woudenberg I, van Etten E, Vulto A Antimicrob Agents Chemother. 2006; 50(5):1852-4.

PMID: 16641459 PMC: 1472188. DOI: 10.1128/AAC.50.5.1852-1854.2006.


Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue.

Schiffelers R, Storm G Pharm Res. 2001; 18(6):780-7.

PMID: 11474781 DOI: 10.1023/a:1011080211226.


Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

ten Kate M, Guo L, Working P, Mouton J Antimicrob Agents Chemother. 2001; 45(5):1487-92.

PMID: 11302815 PMC: 90493. DOI: 10.1128/AAC.45.5.1487-1492.2001.


References
1.
Bennett J, BRODIE J, BENNER E, KIRBY W . Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966; 14(2):170-7. PMC: 546645. DOI: 10.1128/am.14.2.170-177.1966. View

2.
Klastersky J, Weerts D . Recent experience with bacteremia in patients presenting cancer. Eur J Cancer (1965). 1973; 9(1):69-76. DOI: 10.1016/0014-2964(73)90045-5. View

3.
REED W . Indolent pulmonary abscess associated with Klebsiella and Enterobacter. Am Rev Respir Dis. 1973; 107(6):1055-9. DOI: 10.1164/arrd.1973.107.6.1055. View

4.
Umsawasdi T, Middleman E, Luna M, Bodey G . Klebsiella bacteremia in cancer patients. Am J Med Sci. 1973; 265(6):473-82. DOI: 10.1097/00000441-197306000-00006. View

5.
Gaya H, Tattersall M, Hutchinson R, Spiers A . Changing patterns of infection in cancer patients. Eur J Cancer (1965). 1973; 9(6):401-6. DOI: 10.1016/0014-2964(73)90104-7. View